Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on Bilayer properties, biodistribution, and immune responses

Randip Kaur, Malou Henriksen-Lacey, Jitinder Wilkhu, Andrew Devitt, Dennis Christensen, Yvonne Perrie

Research output: Contribution to journalArticle

Abstract

Cholesterol is an abundant component of mammalian cell membranes and has been extensively studied as an artificial membrane stabilizer in a wide range of phospholipid liposome systems. In this study, the aim was to investigate the role of cholesterol in cationic liposomal adjuvant system based on dimethyldioctadecylammonium (DDA) and trehalose 6,6'-dibehenate (TDB) which has been shown as a strong adjuvant system for vaccines against a wide range of diseases. Packaging of cholesterol within DDA:TDB liposomes was investigated using differential scanning calorimetery and surface pressure-area isotherms of lipid monolayers; incorporation of cholesterol into liposomal membranes promoted the formation of a liquid-condensed monolayer and removed the main phase transition temperature of the system, resulting in an increased bilayer fluidity and reduced antigen retention in vitro. In vivo biodistribution studies found that this increase in membrane fluidity did not alter deposition of liposomes and antigen at the site of injection. In terms of immune responses, early (12 days after immunization) IgG responses were reduced by inclusion of cholesterol; thereafter there were no differences in antibody (IgG, IgG1, IgG2b) responses promoted by DDA:TDB liposomes with and without cholesterol. However, significantly higher levels of IFN-gamma were induced by DDA:TDB liposomes, and liposome uptake by macrophages in vitro was also shown to be higher for DDA:TDB liposomes compared to their cholesterol-containing counterparts, suggesting that small changes in bilayer mechanics can impact both cellular interactions and immune responses. © 2013 American Chemical Society.
LanguageEnglish
Pages197-207
Number of pages11
JournalMolecular Pharmaceutics
Volume11
Issue number1
Early online date20 Nov 2013
DOIs
Publication statusPublished - 6 Jan 2014

Fingerprint

Liposomes
Cholesterol
Membrane Fluidity
Immunoglobulin G
Artificial Membranes
Antigens
Transition Temperature
Phase Transition
Product Packaging
dimethyldioctadecylammonium
trehalose 6,6'-dibehenate
Mechanics
Cellular Immunity
Immunization
Phospholipids
Vaccines
Macrophages
Cell Membrane
Lipids
Pressure

Bibliographical note

Funding: This work was partly funded by NewTBVAC (contract no. HEALTHF3-2009-241745). NewTBVAC has been made possible by contributions from the European Commission.

Keywords

  • vaccine
  • subunit antigen
  • liposomes
  • DDA
  • bilayer fluidity
  • biodistribution
  • adjuvant
  • cholesterol

Cite this

Kaur, Randip ; Henriksen-Lacey, Malou ; Wilkhu, Jitinder ; Devitt, Andrew ; Christensen, Dennis ; Perrie, Yvonne. / Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on Bilayer properties, biodistribution, and immune responses. In: Molecular Pharmaceutics. 2014 ; Vol. 11, No. 1. pp. 197-207.
@article{6f0ee2030c184606ba4adea18e7cdbc3,
title = "Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on Bilayer properties, biodistribution, and immune responses",
abstract = "Cholesterol is an abundant component of mammalian cell membranes and has been extensively studied as an artificial membrane stabilizer in a wide range of phospholipid liposome systems. In this study, the aim was to investigate the role of cholesterol in cationic liposomal adjuvant system based on dimethyldioctadecylammonium (DDA) and trehalose 6,6'-dibehenate (TDB) which has been shown as a strong adjuvant system for vaccines against a wide range of diseases. Packaging of cholesterol within DDA:TDB liposomes was investigated using differential scanning calorimetery and surface pressure-area isotherms of lipid monolayers; incorporation of cholesterol into liposomal membranes promoted the formation of a liquid-condensed monolayer and removed the main phase transition temperature of the system, resulting in an increased bilayer fluidity and reduced antigen retention in vitro. In vivo biodistribution studies found that this increase in membrane fluidity did not alter deposition of liposomes and antigen at the site of injection. In terms of immune responses, early (12 days after immunization) IgG responses were reduced by inclusion of cholesterol; thereafter there were no differences in antibody (IgG, IgG1, IgG2b) responses promoted by DDA:TDB liposomes with and without cholesterol. However, significantly higher levels of IFN-gamma were induced by DDA:TDB liposomes, and liposome uptake by macrophages in vitro was also shown to be higher for DDA:TDB liposomes compared to their cholesterol-containing counterparts, suggesting that small changes in bilayer mechanics can impact both cellular interactions and immune responses. {\circledC} 2013 American Chemical Society.",
keywords = "vaccine, subunit antigen, liposomes, DDA, bilayer fluidity, biodistribution, adjuvant, cholesterol",
author = "Randip Kaur and Malou Henriksen-Lacey and Jitinder Wilkhu and Andrew Devitt and Dennis Christensen and Yvonne Perrie",
note = "Funding: This work was partly funded by NewTBVAC (contract no. HEALTHF3-2009-241745). NewTBVAC has been made possible by contributions from the European Commission.",
year = "2014",
month = "1",
day = "6",
doi = "10.1021/mp400372j",
language = "English",
volume = "11",
pages = "197--207",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "1",

}

Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on Bilayer properties, biodistribution, and immune responses. / Kaur, Randip; Henriksen-Lacey, Malou; Wilkhu, Jitinder; Devitt, Andrew; Christensen, Dennis; Perrie, Yvonne.

In: Molecular Pharmaceutics, Vol. 11, No. 1, 06.01.2014, p. 197-207.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on Bilayer properties, biodistribution, and immune responses

AU - Kaur, Randip

AU - Henriksen-Lacey, Malou

AU - Wilkhu, Jitinder

AU - Devitt, Andrew

AU - Christensen, Dennis

AU - Perrie, Yvonne

N1 - Funding: This work was partly funded by NewTBVAC (contract no. HEALTHF3-2009-241745). NewTBVAC has been made possible by contributions from the European Commission.

PY - 2014/1/6

Y1 - 2014/1/6

N2 - Cholesterol is an abundant component of mammalian cell membranes and has been extensively studied as an artificial membrane stabilizer in a wide range of phospholipid liposome systems. In this study, the aim was to investigate the role of cholesterol in cationic liposomal adjuvant system based on dimethyldioctadecylammonium (DDA) and trehalose 6,6'-dibehenate (TDB) which has been shown as a strong adjuvant system for vaccines against a wide range of diseases. Packaging of cholesterol within DDA:TDB liposomes was investigated using differential scanning calorimetery and surface pressure-area isotherms of lipid monolayers; incorporation of cholesterol into liposomal membranes promoted the formation of a liquid-condensed monolayer and removed the main phase transition temperature of the system, resulting in an increased bilayer fluidity and reduced antigen retention in vitro. In vivo biodistribution studies found that this increase in membrane fluidity did not alter deposition of liposomes and antigen at the site of injection. In terms of immune responses, early (12 days after immunization) IgG responses were reduced by inclusion of cholesterol; thereafter there were no differences in antibody (IgG, IgG1, IgG2b) responses promoted by DDA:TDB liposomes with and without cholesterol. However, significantly higher levels of IFN-gamma were induced by DDA:TDB liposomes, and liposome uptake by macrophages in vitro was also shown to be higher for DDA:TDB liposomes compared to their cholesterol-containing counterparts, suggesting that small changes in bilayer mechanics can impact both cellular interactions and immune responses. © 2013 American Chemical Society.

AB - Cholesterol is an abundant component of mammalian cell membranes and has been extensively studied as an artificial membrane stabilizer in a wide range of phospholipid liposome systems. In this study, the aim was to investigate the role of cholesterol in cationic liposomal adjuvant system based on dimethyldioctadecylammonium (DDA) and trehalose 6,6'-dibehenate (TDB) which has been shown as a strong adjuvant system for vaccines against a wide range of diseases. Packaging of cholesterol within DDA:TDB liposomes was investigated using differential scanning calorimetery and surface pressure-area isotherms of lipid monolayers; incorporation of cholesterol into liposomal membranes promoted the formation of a liquid-condensed monolayer and removed the main phase transition temperature of the system, resulting in an increased bilayer fluidity and reduced antigen retention in vitro. In vivo biodistribution studies found that this increase in membrane fluidity did not alter deposition of liposomes and antigen at the site of injection. In terms of immune responses, early (12 days after immunization) IgG responses were reduced by inclusion of cholesterol; thereafter there were no differences in antibody (IgG, IgG1, IgG2b) responses promoted by DDA:TDB liposomes with and without cholesterol. However, significantly higher levels of IFN-gamma were induced by DDA:TDB liposomes, and liposome uptake by macrophages in vitro was also shown to be higher for DDA:TDB liposomes compared to their cholesterol-containing counterparts, suggesting that small changes in bilayer mechanics can impact both cellular interactions and immune responses. © 2013 American Chemical Society.

KW - vaccine

KW - subunit antigen

KW - liposomes

KW - DDA

KW - bilayer fluidity

KW - biodistribution

KW - adjuvant

KW - cholesterol

UR - http://www.scopus.com/inward/record.url?scp=84891807469&partnerID=8YFLogxK

UR - https://pubs.acs.org/doi/10.1021/mp400372j

U2 - 10.1021/mp400372j

DO - 10.1021/mp400372j

M3 - Article

VL - 11

SP - 197

EP - 207

JO - Molecular Pharmaceutics

T2 - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 1

ER -